Menu Search
Equities

CareDx Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1K9:MUN

CareDx Inc

Actions
  • Price (EUR)16.83
  • Today's Change-0.270 / -1.58%
  • Shares traded10.00
  • 1 Year change-24.39%
  • Beta2.5145
Data delayed at least 15 minutes, as of Feb 12 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.

  • Revenue in USD (TTM)358.00m
  • Net income in USD60.76m
  • Incorporated1998
  • Employees644.00
  • Location
    CareDx Inc8000 Marina Blvd, 4Th FloorBRISBANE 94005United StatesUSA
  • Phone+1 (415) 287-2300
  • Fax+1 (302) 636-5454
  • Websitehttps://www.caredx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.